Richard Gaynor

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine (Los Angeles, CA) for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002.^[1][2] His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews.^[3][4][5][6] He has been a top executive at several pharmaceutical companies,^[7] with respect to the development and clinical testing of novel anticancer drugs and cell therapies.^[8][9] For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013.^[10] Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA.^[11][12] His honors include being elected a member of the American Society for Clinical Investigation,^[13] and the Association of American Physicians.^[14]